A Phase 2/3 interventional study of Ombitasvir/paritaprevir/ritonavir and Dasabuvir in Chronic Hepatitis C Infection, sponsored by AbbVie. Completed at 21 sites in 5 countries. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-10-05.
Sponsored by AbbVie · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing Ombitasvir/Paritaprevir/Ritonavir in Hepatitis C — none open to participants now, none under way, none of them phase 3. Ombitasvir/Paritaprevir/Ritonavir · Hepatitis C.
Among the 12 studies testing Ombitasvir/Paritaprevir/Ritonavir in Hepatitis C, this one is the 6th largest by enrollment, is one of 4 that started in 2015, is the only one in phase 2/3, and was the 8th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 12 studies testing Ombitasvir/Paritaprevir/Ritonavir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 3 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 9 · Phase 4 1
First in 2013; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is below the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 62 across the 12 interventional studies. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 12 have an industry lead sponsor. The 2 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
90 studies in Hepatitis C by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 88 finished, 71 (81%) have results posted.
Among the 90 studies in Hepatitis C by AbbVie, this one is the 56th largest by enrollment of the 74 interventional ones that give a count, is one of 19 that started in 2015, is one of 6 in phase 2/3, and was the 47th registered.
AbbVie’s Hepatitis C studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing Ombitasvir/Paritaprevir/Ritonavir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 90 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a Phase 2/3, open-label, multicenter study to evaluate the pharmacokinetics (PK), efficacy, and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) with or without dasabuvir (DSV) and with or without ribavirin (RBV) in Hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4)-infected pediatric participants of ≥ 3 to 17 years of age.
The study population for Part 1, the PK study, included GT1-infected participants who were noncirrhotic and treatment-naïve (TN). Part 2, the safety and efficacy study, included GT1 or GT4-infected participants who were TN or interferon ([IFN] or Pegylated-interferon alfa-2a or 2b [pegIFN] with or without RBV) treatment-experienced (TE) without cirrhosis or with compensated cirrhosis. In Part 1 and Part 2, the treatment regimen and duration were dependent on HCV GT, GT1 subtype, and cirrhosis status.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with HCV GT1b without cirrhosis received the adult 3-DAA (OBV/PTV/RTV and DSV) regimen: two 12.5 mg ombitasvir /75 mg paritaprevir /50 mg ritonavir tablets taken orally every morning (QD) and one dasabuvir 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis received 12-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label.
Drug: Ombitasvir/paritaprevir/ritonavir · Drug: Dasabuvir · Drug: Ribavirin
Participants with HCV GT1b received the adult 3-DAA (OBV/PTV/RTV and DSV) regimen: two 12.5 mg ombitasvir /75mg paritaprevir /50 mg ritonavir tablets taken orally every morning (QD) and one dasabuvir 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis received 12-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label. Participants with HCV GT1a with compensated cirrhosis received 24-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label. Participants with HCV GT4 received 12-week treatment with the OBV/PTV/RTV formulation and ribavirin 200 mg tablets were administered orally per local label.
Drug: Ombitasvir/paritaprevir/ritonavir · Drug: Dasabuvir · Drug: Ribavirin
Participants with HCV GT1b without cirrhosis were to receive the mini-tablet 3-DAA (OBV, PTV, RTV, and DSV) regimen for 12 weeks: ombitasvir 0.3 mg, paritaprevir 1.0 mg, and ritonavir 1.0 mg mini-tablets administered orally QD based on body weight and dasabuvir taken orally BID as 3.08 mg mini-tablets based on body weight. Participants with HCV GT1a without cirrhosis received 12-week treatment with the mini-tablet 3-DAA regimen and ribavirin was provided as a 40 mg/mL oral solution and administered per local label.
Drug: Ombitasvir mini tablet · Drug: Paritaprevir mini tablet · Drug: Ritonavir mini tablet · Drug: Dasabuvir mini tablet · Drug: Ribavirin solution
Participants with HCV GT1b without cirrhosis were to receive the mini-tablet 3-DAA (OBV, PTV, RTV, and DSV) regimen for 12 weeks: ombitasvir 0.3 mg, paritaprevir 1.0 mg, and ritonavir 1.0 mg mini-tablets administered orally QD based on body weight and dasabuvir taken orally BID as 3.08 mg mini-tablets based on body weight. Participants with HCV GT1a without cirrhosis received 12-week treatment with the mini-tablet 3-DAA regimen and ribavirin was provided as a 40 mg/mL oral solution and administered per local label.
Drug: Ombitasvir mini tablet · Drug: Paritaprevir mini tablet · Drug: Ritonavir mini tablet · Drug: Dasabuvir mini tablet · Drug: Ribavirin solution
Drug page: Ombitasvir/Paritaprevir/Ritonavir
Film-coated tablet for oral use
Also known as: Ombitasvir also known as ABT-267, Paritaprevir also known as ABT-450, Ombitsvir/paritaprevir/ritonavir also known as Viekirax
Film-coated tablet for oral use
Also known as: Exviera, ABT-333
Film-coated tablet for oral use
Film-coated tablet for oral use
Also known as: ABT-267
Film-coated tablet for oral use
Also known as: ABT-450
Film-coated tablet for oral use
Film-coated tablet for oral use
Also known as: Exviera, ABT-333
Oral solution
Part 1: Maximum Plasma Concentration (Cmax) of Ombitasvir (OBV)
Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.
Time frame: At Week 2
Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Ombitasvir (OBV)
AUC is a measure of how long and how much drug is present in the body after dosing. The amount of ombitasvir present was measured up to 24 hours after dosing.
Time frame: At Week 2
Part 1: Lowest Plasma Concentration (Ctrough) of Ombitasvir (OBV)
Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.
Time frame: At Weeks 2 and 8
Part 1: Maximum Plasma Concentration (Cmax) of Paritaprevir (PTV)
Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.
Time frame: At Week 2
Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Paritaprevir (PTV)
AUC is a measure of how long and how much drug is present in the body after dosing. The amount of paritaprevir present was measured up to 24 hours after dosing.
Time frame: At Week 2
Part 1: Lowest Plasma Concentration (Ctrough) of Paritaprevir (PTV)
Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.
Time frame: At Weeks 2 and 8
Part 1: Maximum Plasma Concentration (Cmax) of Dasabuvir (DSV)
Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.
Time frame: At Week 2
Part 1: Concentration of Drug in Blood Plasma Against Time [Area Under the Curve (AUC)] of Dasabuvir (DSV)
AUC is a measure of how long and how much drug is present in the body after dosing. The amount of dasabuvir present was measured up to 12 hours after dosing. For two subjects in the 15-29 kg group, the 24 h concentration was used as the 12 h concentration due to the significant sampling time deviation. For one subject in the 30-44 kg group, the 24 h concentration was used as the 12 h concentration due to the significant sampling time deviation.
Time frame: At Week 2
Part 1: Lowest Plasma Concentration (Ctrough) of Dasabuvir (DSV)
Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.
Time frame: At Weeks 2 and 8
Part 1: Maximum Plasma Concentration (Cmax) of Ritonavir (RTV)
Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.
Time frame: At Week 2
Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Ritonavir (RTV)
AUC is a measure of how long and how much drug is present in the body after dosing. The amount of ritonavir present was measured up to 24 hours after dosing.
Time frame: At Week 2
Part 1: Lowest Plasma Concentration (Ctrough) of Ritonavir (RTV)
Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.
Time frame: At Weeks 2 and 8
Parts 1 and 2: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Last Actual Dose of Study Drug (SVR12)
SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) \< lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug.
Time frame: 12 weeks after last dose of study drug (Week 24 or 36 depending on treatment duration)
Parts 1 and 2: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Last Actual Dose of Study Drug (SVR12) Summarized by Formulation, Age and Weight Group, and Across All Subjects on the Adult Formulations
SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) \< lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug.
Time frame: 12 weeks after last dose of study drug (Week 24 or 36 depending on treatment duration)
Parts 1 & 2: Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Actual Dose of Study Drug (SVR24), Summarized by Formulation, Age and Weight Group, Across All Subjects, and Across All Subjects on the Adult Formulations
SVR24 is defined as hepatitis C virus ribonucleic acid (HCV RNA) \< lower limit of quantification (LLOQ) 24 weeks after the last actual dose of study drug.
Time frame: 24 weeks after last dose of study drug (Week 36 or 48 depending on treatment duration)
Parts 1 and 2: Percentage of Participants With Alanine Aminotransferase (ALT) Normalization During Treatment by Formulation, Age and Weight Group, Across All Subjects, and Across All Subjects on the Adult Formulations
Alanine aminotransferase (ALT) normalization during treatment is defined as ALT ≤ the upper limit of normal (ULN) at the final treatment visit for participants with ALT \> ULN at baseline.
Time frame: 12 or 24 weeks after starting study drug, depending on treatment duration
| Milestone | Adult Tablet, 12-17 yr, Part 1 | Adult Tablet, 12-17 yr, Part 2 | Mini Tablet, 9-11 yr, Part 1 | Mini Tablet, 3-8 yr, Part 1 |
|---|---|---|---|---|
| Started | 12 | 26 | 12 | 14 |
| Completed | 10 | 23 | 10 | 10 |
| Not completed | 2 | 3 | 2 | 4 |
| Withdrew: Withdrew consent | 1 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 3 | 1 | 3 |
| Withdrew: Other, not specified | 0 | 0 | 1 | 0 |
Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.
| ng/mL | 15 - 29 kg Body Weight | 30 - 44 kg Body Weight | ≥ 45 kg Body Weight |
|---|---|---|---|
| Part 1: Maximum Plasma Concentration (Cmax) of Ombitasvir (OBV) | 99.6 ± 27 | 116 ± 14 | 83.7 ± 39 |
AUC is a measure of how long and how much drug is present in the body after dosing. The amount of ombitasvir present was measured up to 24 hours after dosing.
| ng•h/mL | 15 - 29 kg Body Weight | 30 - 44 kg Body Weight | ≥ 45 kg Body Weight |
|---|---|---|---|
| Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Ombitasvir (OBV) | 1270 ± 26 | 1490 ± 12 | 1060 ± 43 |
Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.
| ng/mL | 15 - 29 kg Body Weight | 30 - 44 kg Body Weight | ≥ 45 kg Body Weight |
|---|---|---|---|
| Week 2 | 24.7 ± 32 | 28.2 ± 16 | 21.8 ± 39 |
| Week 8 | 29.6 ± 78 | 30.4 ± 24 | 20.9 ± 58 |
Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.
| ng/mL | 15 - 29 kg Body Weight | 30 - 44 kg Body Weight | ≥ 45 kg Body Weight |
|---|---|---|---|
| Part 1: Maximum Plasma Concentration (Cmax) of Paritaprevir (PTV) | 294 ± 152 | 1540 ± 71 | 870 ± 125 |
AUC is a measure of how long and how much drug is present in the body after dosing. The amount of paritaprevir present was measured up to 24 hours after dosing.
| ng•h/mL | 15 - 29 kg Body Weight | 30 - 44 kg Body Weight | ≥ 45 kg Body Weight |
|---|---|---|---|
| Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Paritaprevir (PTV) | 2180 ± 136 | 8640 ± 90 | 5770 ± 152 |
Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.
| ng/mL | 15 - 29 kg Body Weight | 30 - 44 kg Body Weight | ≥ 45 kg Body Weight |
|---|---|---|---|
| Week 2 | 9.86 ± 113 | 16.1 ± 112 | 18.0 ± 78 |
| Week 8 | 17.3 ± 136 | 18.4 ± 89 | 23.5 ± 86 |
Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.
| ng/mL | 15 - 29 kg Body Weight | 30 - 44 kg Body Weight | ≥ 45 kg Body Weight |
|---|---|---|---|
| Part 1: Maximum Plasma Concentration (Cmax) of Dasabuvir (DSV) | 579 ± 44 | 830 ± 45 | 671 ± 48 |
AUC is a measure of how long and how much drug is present in the body after dosing. The amount of dasabuvir present was measured up to 12 hours after dosing. For two subjects in the 15-29 kg group, the 24 h concentration was used as the 12 h concentration due to the significant sampling time deviation. For one subject in the 30-44 kg group, the 24 h concentration was used as the 12 h concentration due to the significant sampling time deviation.
| ng•h/mL | 15 - 29 kg Body Weight | 30 - 44 kg Body Weight | ≥ 45 kg Body Weight |
|---|---|---|---|
| Part 1: Concentration of Drug in Blood Plasma Against Time [Area Under the Curve (AUC)] of Dasabuvir (DSV) | 3960 ± 44 | 5960 ± 47 | 4630 ± 49 |
Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.
| ng/mL | 15 - 29 kg Body Weight | 30 - 44 kg Body Weight | ≥ 45 kg Body Weight |
|---|---|---|---|
| Week 2 | 110 ± 57 | 215 ± 54 | 165 ± 56 |
| Week 8 | 168 ± 82 | 264 ± 65 | 191 ± 60 |
Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.
| ng/mL | 15 - 29 kg Body Weight | 30 - 44 kg Body Weight | ≥ 45 kg Body Weight |
|---|---|---|---|
| Part 1: Maximum Plasma Concentration (Cmax) of Ritonavir (RTV) | 1090 ± 67 | 1830 ± 42 | 1180 ± 35 |
AUC is a measure of how long and how much drug is present in the body after dosing. The amount of ritonavir present was measured up to 24 hours after dosing.
| ng•h/mL | 15 - 29 kg Body Weight | 30 - 44 kg Body Weight | ≥ 45 kg Body Weight |
|---|---|---|---|
| Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Ritonavir (RTV) | 6570 ± 60 | 14100 ± 49 | 8900 ± 37 |
Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.
| ng/mL | 15 - 29 kg Body Weight | 30 - 44 kg Body Weight | ≥ 45 kg Body Weight |
|---|---|---|---|
| Week 2 | 16.1 ± 72 | 32.1 ± 63 | 29.8 ± 54 |
| Week 8 | 91.8 ± 268 | 38.1 ± 112 | 58.2 ± 138 |
SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) \< lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug.
| percentage of participants | All Participants, Total |
|---|---|
| Parts 1 and 2: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Last Actual Dose of Study Drug (SVR12) | 98.4 (91.7 to 99.7) |
SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) \< lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug.
| percentage of participants | Adult Tablet, 12-17 YR, ≥ 45 kg | Mini-tablet, 9-11 YR, 15 to 29 kg | Mini-tablet, 9-11 YR, 30 to 44 kg | Mini-tablet, 9-11 YR, ≥ 45 kg | Mini-tablet, 3-8 YR, 15 to 29 kg | Mini-tablet Total |
|---|---|---|---|---|---|---|
| Parts 1 and 2: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Last Actual Dose of Study Drug (SVR12) Summarized by Formulation, Age and Weight Group, and Across All Subjects on the Adult Formulations | 100 (90.8 to 100.0) | 100 (20.7 to 100.0) | 100 (70.1 to 100.0) | 100 (34.2 to 100.0) | 92.9 (68.5 to 98.7) | 96.2 (81.1 to 99.3) |
SVR24 is defined as hepatitis C virus ribonucleic acid (HCV RNA) \< lower limit of quantification (LLOQ) 24 weeks after the last actual dose of study drug.
| percentage of participants | Participants in Parts 1 and 2 of the Study | Adult Tablet, 12-17 YR, ≥ 45 kg | Mini-tablet, 9-11 YR, 15 to 29 kg | Mini-tablet, 9-11 YR, 30 to 44 kg | Mini-tablet, 9-11 YR, ≥ 45 kg | Mini-tablet, 3-8 YR, 15 to 29 kg | Mini-tablet Total |
|---|---|---|---|---|---|---|---|
| Parts 1 & 2: Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Actual Dose of Study Drug (SVR24), Summarized by Formulation, Age and Weight Group, Across All Subjects, and Across All Subjects on the Adult Formulations | 96.9 (89.3 to 99.1) | 100 (90.8 to 100.0) | 100.0 (20.7 to 100.0) | 88.9 (56.5 to 98.0) | 100.0 (34.2 to 100.0) | 92.9 (68.5 to 98.7) | 92.3 (75.9 to 97.9) |
Alanine aminotransferase (ALT) normalization during treatment is defined as ALT ≤ the upper limit of normal (ULN) at the final treatment visit for participants with ALT \> ULN at baseline.
| percentage of participants | Adult Tablet,12-17 YR, ≥ 45 kg, ALT Normalization | Mini-tablet, 9-11 YR, 15 to 29 kg, ALT Normalization | Mini-tablet, 9-11 YR, 30 to 44 kg, ALT Normalization | Mini-tablet, 3-8 YR, 15 to 29 kg, ALT Normalization | Mini-tablet Total, ALT Normalization | Participants in Parts 1 and 2 of the Study, ALT Normalization |
|---|---|---|---|---|---|---|
| Parts 1 and 2: Percentage of Participants With Alanine Aminotransferase (ALT) Normalization During Treatment by Formulation, Age and Weight Group, Across All Subjects, and Across All Subjects on the Adult Formulations | 87.5 (69.0 to 95.7) | 100 (20.7 to 100.0) | 100 (56.6 to 100.0) | 80.0 (49.0 to 94.3) | 87.5 (64.0 to 96.5) | 87.5 (73.9 to 94.5) |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the first dose of study drug until 30 days after last dose, up to 37 weeks. SAEs and protocol-related nonserious AEs were collected from the time the subject signed consent.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adult Tablet, 12-17 yr, Part 1 | 0/12 (0%) | 0/12 (0%) | 11/12 (91.7%) |
| Adult Tablet, 12-17 yr, Part 2 | 0/26 (0%) | 0/26 (0%) | 17/26 (65.4%) |
| Adult Tablet, 12-17 yr, Total | 0/38 (0%) | 0/38 (0%) | 28/38 (73.7%) |
| Mini Tablet, 9-11 yr, Part 1 | 0/12 (0%) | 1/12 (8.3%) | 12/12 (100%) |
| Mini Tablet, 3-8 yr, Part 1 | 0/14 (0%) | 0/14 (0%) | 9/14 (64.3%) |
| Mini Tablet, Total | 0/26 (0%) | 1/26 (3.8%) | 21/26 (80.8%) |
| All Participants, Total | 0/64 (0%) | 1/64 (1.6%) | 49/64 (76.6%) |
| Event | Adult Tablet, 12-17 yr, Part 1 | Adult Tablet, 12-17 yr, Part 2 | Adult Tablet, 12-17 yr, Total | Mini Tablet, 9-11 yr, Part 1 | Mini Tablet, 3-8 yr, Part 1 | Mini Tablet, Total | All Participants, Total |
|---|---|---|---|---|---|---|---|
| LeukopeniaBlood and lymphatic system disorders | 0/12 | 0/26 | 0/38 | 1/12 | 0/14 | 1/26 | 1/64 |
| NeutropeniaBlood and lymphatic system disorders | 0/12 | 0/26 | 0/38 | 1/12 | 0/14 | 1/26 | 1/64 |
| Event | Adult Tablet, 12-17 yr, Part 1 | Adult Tablet, 12-17 yr, Part 2 | Adult Tablet, 12-17 yr, Total | Mini Tablet, 9-11 yr, Part 1 | Mini Tablet, 3-8 yr, Part 1 | Mini Tablet, Total | All Participants, Total |
|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 2/12 | 5/26 | 7/38 | 5/12 | 1/14 | 6/26 | 13/64 |
| HeadacheNervous system disorders | 3/12 | 5/26 | 8/38 | 5/12 | 2/14 | 7/26 | 15/64 |
| VomitingGastrointestinal disorders | 0/12 | 1/26 | 1/38 | 4/12 | 1/14 | 5/26 | 6/64 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 1/26 | 1/38 | 3/12 | 0/14 | 3/26 | 4/64 |
| NauseaGastrointestinal disorders | 3/12 | 0/26 | 3/38 | 3/12 | 1/14 | 4/26 | 7/64 |
| PyrexiaGeneral disorders | 2/12 | 1/26 | 3/38 | 3/12 | 2/14 | 5/26 | 8/64 |
| Upper respiratory tract infectionInfections and infestations | 2/12 | 2/26 | 4/38 | 1/12 | 3/14 | 4/26 | 8/64 |
| Abdominal painGastrointestinal disorders | 2/12 | 0/26 | 2/38 | 1/12 | 0/14 | 1/26 | 3/64 |
| Abdominal pain upperGastrointestinal disorders | 0/12 | 1/26 | 1/38 | 2/12 | 0/14 | 2/26 | 3/64 |
| FlatulenceGastrointestinal disorders | 0/12 | 0/26 | 0/38 | 2/12 | 0/14 | 2/26 | 2/64 |
Intention-to-treat population: all participants who received at least one dose of study drug in Part 1 or Part 2
| Age, Continuous(years) | Adult Tablet, 12-17 yr, Part 1 | Adult Tablet, 12-17 yr, Part 2 | Mini Tablet, 9-11 yr, Part 1 | Mini Tablet, 3-8 yr, Part 1 | Total |
|---|---|---|---|---|---|
| Mean | 15.4 ± 1.73 | 15.0 ± 1.68 | 9.8 ± 0.83 | 4.8 ± 1.67 | 11.9 ± 4.54 |
| Sex: Female, Male(Participants) | Adult Tablet, 12-17 yr, Part 1 | Adult Tablet, 12-17 yr, Part 2 | Mini Tablet, 9-11 yr, Part 1 | Mini Tablet, 3-8 yr, Part 1 | Total |
|---|---|---|---|---|---|
| Female | 9 | 16 | 6 | 11 | 42 |
| Male | 3 | 10 | 6 | 3 | 22 |
| Race/Ethnicity, Customized(Participants) | Adult Tablet, 12-17 yr, Part 1 | Adult Tablet, 12-17 yr, Part 2 | Mini Tablet, 9-11 yr, Part 1 | Mini Tablet, 3-8 yr, Part 1 | Total |
|---|---|---|---|---|---|
| White | 6 | 23 | 10 | 10 | 49 |
| Black or African American | 2 | 3 | 0 | 4 | 9 |
| Asian | 3 | 0 | 1 | 0 | 4 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Multi race | 1 | 0 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Oct 2015 to primary completion in Nov 2020, 60 months.
Results were first posted in Oct 2021, 10 months after primary completion.
Of 14 phase 2/3 interventional studies under Hepatitis C, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 51. This study's 60 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ombitasvir/Paritaprevir/Ritonavir · Ribavirin